Roivant to present phase 2 pulmonary hypertension study results

Roivant and Pulmovant are set to unveil the results of their Phase 2 PHOCUS study on the use of mosliciguat for pulmonary hypertension in patients with interstitial lung disease. The presentation is scheduled for September 8, 2026, at 12:15 CEST during the European Respiratory Society International Congress 2026. Marc Humbert, a leading expert in the field, will deliver the findings.

Following the presentation, Roivant will host an investor call and webcast at 8:00 a.m. ET, which will be available on the company's website, with an archived version accessible afterward. Mosliciguat is an inhalable sGC activator currently being developed for pulmonary hypertension associated with interstitial lung disease. Other key projects in Roivant's pipeline include LISRAYA, approved by the FDA for treating dermatomyositis in adults, and IMVT-1402, a monoclonal antibody targeting FcRn.

Roivant is a commercial-stage biopharmaceutical company dedicated to developing and commercializing medicines through its subsidiary companies called Vants.